经皮冠状动脉介入治疗后白细胞计数升高与长期死亡率的关系。

Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality.

作者信息

Rajagopal Vivek, Gurm Hitinder S, Bhatt Deepak L, Lincoff A Michael, Tcheng James E, Kereiakes Dean J, Kleiman Neal S, Jia Gang, Topol Eric J

机构信息

The Cleveland Clinic Foundation, Cleveland, Ohio, USA.

出版信息

Am J Cardiol. 2004 Jul 15;94(2):190-2. doi: 10.1016/j.amjcard.2004.03.060.

DOI:10.1016/j.amjcard.2004.03.060

PMID:15246898

Abstract

Increased inflammatory markers are associated with a poor prognosis after percutaneous coronary intervention. Leukocytes play a key role in inflammation, and an increase in white blood cell (WBC) counts is a nonspecific marker of inflammation. In patients undergoing percutaneous coronary intervention, baseline WBC counts independently predict long-term mortality. In a pooled cohort of patients from the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC), the Evaluation in PTCA to Improve Long-term Outcome with abciximab Glycoprotein IIb/IIIa blockade (EPILOG), and Evaluation of Platelet IIb/IIIa inhibitor for STENTing (EPISTENT) trials, postprocedural WBC counts were also found to be an independent predictor of long-term mortality.

摘要

炎症标志物升高与经皮冠状动脉介入治疗后的不良预后相关。白细胞在炎症中起关键作用，白细胞计数增加是炎症的非特异性标志物。在接受经皮冠状动脉介入治疗的患者中，基线白细胞计数可独立预测长期死亡率。在来自预防缺血性并发症的c7E3评估（EPIC）、使用阿昔单抗糖蛋白IIb/IIIa阻断改善经皮冠状动脉腔内血管成形术（PTCA）长期结果的评估（EPILOG）以及支架置入血小板IIb/IIIa抑制剂评估（EPISTENT）试验的合并队列患者中，术后白细胞计数也被发现是长期死亡率的独立预测指标。